PureTech Health plc
PRTCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, PureTech Health plc (PRTC) is listed under Biotechnology. The $424.0M market capitalization puts PRTC squarely in small-cap range for its industry. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Market Cap
$424.0M
Beta
0.79
P/E (TTM)
—
P/E (Fwd)
-34.84
EPS (TTM)
$-4.60
EPS (Fwd)
$-0.50
ROE
-30.9%
ROA
-10.8%
Cash
$288.7M
Total Debt
$203.3M
Free CF
-$90.0M
52W Change
-8.3%
Annual Financials
Cash vs Debt
PureTech Health plc holds $288.7M in cash against $203.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$90.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -30.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $2.1M (2022) to $4.7M (2025), reflecting a 123% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence PureTech Health plc's trajectory.